What Happened?
San Diego,, CA-based Pipeline-Therapeutics Appointed Carmine Stengone as Chief Executive Officer
About the Company
Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair. The company`s lead product candidate, PIPE-505, is a small molecule gamma secretase inhibitor (GSI) to treat mild-to-moderate sensorineural hearing loss (SNHL) associated with cochlear synaptopathy. The company also has a portfolio of programs, including PIPE-307, focused on remyelination and axonal repair, to address a range of neurological disorders, including multiple sclerosis.
About the Person
Carmine Stengone is Chief Executive Officer at Pipeline Therapeutics. Previously, Carmine held various senior HR leadership roles in the industry.
Info Source
News
Short Profile